This is not the most recent version of the article. View current version (30 OCT 2014)

Intervention Protocol

You have free access to this content

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria

  1. Arturo J Martí-Carvajal1,*,
  2. Vidhu Anand2,
  3. Andrés Felipe Cardona3,
  4. Ivan Solà4

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 28 FEB 2013

DOI: 10.1002/14651858.CD010340


How to Cite

Martí-Carvajal AJ, Anand V, Cardona AF, Solà I. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD010340. DOI: 10.1002/14651858.CD010340.

Author Information

  1. 1

    Universidad Tecnológica Equinoccial, Facultad de Ciencias de la Salud Eugenio Espejo, Quito, Ecuador

  2. 2

    University of Minnesota, Department of Surgery, Minneapolis, Minnesota, USA

  3. 3

    Institute of Oncology, Fundación Santa Fe de Bogotá, Clinical and Translational Oncology Group, Bogotá, Cundinamarca, Colombia

  4. 4

    Institute of Biomedical Research (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Catalunya, Spain

*Arturo J Martí-Carvajal, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador. arturo.marti.carvajal@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

This is not the most recent version of the article. View current version (30 OCT 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the clinical efficacy and safety of eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria, and to evaluate which patients might benefit most from its use.